NSAID-exacerbated respiratory disease: Clinical review and referral pathway in British Columbia

ABSTRACT: NSAID-exacerbated respiratory disease (NERD) is a triad of asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity reactions to NSAIDs. NERD is common, and increased awareness is needed. NERD patients have severe uncontrolled asthma and require multiple sinus surgeries. We have created a referral pathway to provide NERD patients in British Columbia with access to multidisciplinary care in order to promptly address the different aspects of the disease.

In BC, greater awareness of NSAID-exacerbated respiratory disease, a complex airway disease, is needed to provide early diagnosis and appropriate management.

NSAID-exacerbated respiratory disease (NERD) is a non-IgE hyper­sensitivity reaction that causes a spectrum of symptoms, including chronic rhinosinusitis with nasal polyposis, asthma, and hypersensitivity reactions to NSAIDs (e.g., aspirin, ibuprofen, naproxen).[1] The triad of symptoms is also referred to as Samter’s triad and aspirin-exacerbated respiratory disease. The pathophysiology is thought to be due to abnormalities in arachidonic acid biosynthesis. Through the COX-1 and 5-lipoxygenase pathways, there is an overproduction of cysteinyl leukotrienes and a decrease in downstream anti-inflammatory prostaglandins such as prostaglandin E2. Without the inhibitory effect of the COX-1 pathway by-products, a pro-inflammatory environment is created.[2] However, multiple mechanisms regarding the underlying pathophysiology and associated clinical consequences are currently being investigated.[1]

Clinical presentation

NERD patients often present with a triad of symptoms: NSAID hypersensitivity, asthma, and chronic rhinosinusitis with nasal polyposis. NSAID hypersensitivity is due to COX-1 inhibition and presents with upper/lower airway symptoms. NSAID reactions can occur between 1 and 4 hours after exposure and are dose dependent. Patients may be able to tolerate 80 mg of ASA but react at 160 mg. Reactions are not always reliable; in a cohort of 28 patients who were challenged multiple times, 11 had different responses during the challenges.[3] In some cases, NERD patients can react to acetaminophen at doses higher than 1000 mg because acetaminophen is a weak COX-1 inhibitor.[4]

Asthma is difficult to control in NERD patients. A study that compared 2848 NSAID-tolerant patients with asthma and 459 NERD patients showed that the NERD patients had increased use of oral steroids and visits to the emergency department and a higher rate of intubations.[5]

Chronic rhinosinusitis with nasal polyposis presents with chronic nasal obstruction, anosmia, and recurrent facial pain. The symptoms are caused by the overgrowth of nasal polyps in the nasal cavity [Figure 1].

NERD patients have a tenfold higher risk of sinus disease recurrence after surgery compared with other forms of chronic rhinosinusitis with nasal polyposis.[6] These patients also report hypersensitivity to alcohol, hearing loss, and noncardiac chest pain.[7]

NERD is common: 7.2% of patients with asthma and 8.7% to 10.0% of patients with chronic rhinosinusitis with nasal polyposis have the disease.[8] NERD has a prevalence of 0.3% to 2.5%, and it is estimated that there are 1.5 million patients in the United States.[9] Females are primarily affected, and the average age of onset is 30 years.[7] However, 3.5% to 6.0% of NERD patients may present in childhood.[10,11]


NERD is a clinical diagnosis. While asthma and chronic rhinosinusitis with nasal polyposis can be easily diagnosed, NSAID hypersensitivity is more challenging. If the history of NSAID hypersensitivity is unclear, an ASA challenge must be performed [Table 1].[12] The protocol for challenge and desensitization is the same. The key difference is that patients will continue to take ASA after desensitization. The initial workup includes a complete blood count with differential, rhinoscopy, CT sinus, and pulmonary function tests.[7] Other tests, such as nasal fractional exhaled nitric oxide after ASA ingestion and urine leukotriene E4, can be elevated but are not available in British Columbia.[7]

Allergists, respirologists, and otolaryngologists often treat NERD patients in subspecialty silos. Each specialist focuses on their area of expertise and may miss the diagnosis or not address the multisystem nature of NERD.


The current treatment of NERD involves a combination of medical and surgical management.[1] Medical management can involve a stepwise or often arbitrary constellation of intranasal and inhaled corticosteroids, leukotriene modifiers, aspirin desensitization therapy, and monoclonal antibodies.[1] Table 2 provides a summary of treatment modalities. With intranasal corticosteroids, the first line of management in chronic rhinosinusitis with nasal polyposis, large-volume irrigation is preferred because it reaches deeper into the sinus cavities. Combination inhaled corticosteroids and long-acting bronchodilators are the mainstay management of moderate to severe asthma; the Canadian Thoracic Society asthma guidelines provide further details. Leukotriene receptor antagonists can be helpful in managing NERD patients, but clinicians must be aware of the black box warning and counsel patients about neuropsychiatric side effects, including suicidal ideation.[13] Surgical management usually involves a combination of polypectomies and functional endoscopic sinus surgery to open the sinuses and create a greater surface area for administering intranasal steroids.[2] Many patients require revision surgery that targets mainly the frontal sinus through an extended Draf III procedure, which involves drilling out the surrounding bone and creating a common frontal sinus cavity to aid in the delivery of topical medication postoperatively.[14] Only a few subspecialized rhinologists in BC offer Draf III.

Biologics have revolutionized the management of NERD. Currently, there are three approved biologics for NERD: dupilumab (anti-IL4 receptor alpha), mepolizumab (anti-IL5), and omalizumab (anti-IgE). A meta-analysis that compared different biologics among themselves and with ASA desensitization indicated that dupilumab showed the most significant patient and clinically meaningful outcomes.[15] There are no head-to-head studies between biologics; thus, caution should be used in interpreting the results of the meta-analysis. Yong and colleagues showed that over 10 years, per patient, appropriate medical management after functional endoscopic sinus surgery cost $54 125.31 and resulted in 2.25 revision functional endoscopic sinus surgeries, ASA desensitization after functional endoscopic sinus surgery cost slightly less and resulted in a 10% decrease in revision functional endoscopic sinus surgery, ASA desensitization with salvage dupilumab cost 2.25 times more and resulted in 17% fewer revisions, and up-front dupilumab cost 3.44 times more and resulted in 33% fewer revisions.[16] Although up-front dupilumab leads to better outcomes, it is not cost-effective. Furthermore, NERD patients will need to stay on biologics for the rest of their lives; those who come off dupilumab will have polyp recurrence.[10] Extended functional endoscopic sinus surgery, steroids, and aspirin desensitization therapy have been shown to reduce polyp recurrence rate in NERD patients, thereby reducing overall health care costs while improving patient outcomes.[17]

Aspirin desensitization therapy is a cumbersome and time-consuming procedure and requires subspecialized care, which is available only in Vancouver. Access to aspirin desensitization therapy has been very limited in BC for years. The COVID-19 pandemic made office spirometry challenging to perform due to complex infection control protocols. Aspirin desensitization therapy has risks, such as gastrointestinal bleeding, tinnitus, and kidney injury. We use proton pump inhibitors to prevent gastrointestinal bleeds. There are various proposed treatment algorithms, but the most common involves slowly administering increasing doses of ASA until a reaction is elicited [Table 1].[12] Most protocols administer doses every 90 minutes to 3 hours and can take up to 2 days to complete. Then a maintenance dose of 325 mg to 650 mg orally twice daily is established for continued treatment.[1] Typically, aspirin desensitization therapy is started 3 to 4 weeks after the patient’s first functional endoscopic sinus surgery.[1]

Aspirin Exacerbated Respiratory Disease Clinic

The Aspirin Exacerbated Respiratory Disease (AERD) Clinic was started in November 2021 at St. Paul’s Hospital in Vancouver to help facilitate interdisciplinary care and optimize outcomes. The clinic pays homage to the dated name of AERD over NERD because most clinicians are unfamiliar with the new term. Dr Ruiz (allergist) and Dr Thamboo (rhinologist) created the AERD clinic, which offers ASA challenge/desensitization, surgical consultation, biologics start, follow-up with endoscopy, and optimization of medical and lifestyle management. Baseline biological markers through allergy testing and serology are collected as preoperative endoscopy scores. Patients who are eligible for surgical intervention proceed with functional endoscopic sinus surgery and postoperative aspirin desensitization therapy if deemed appropriate. These patients can also participate in multiple landmark research studies that investigate AERD, aspirin desensitization therapy, and functional endoscopic sinus surgery.

Although biologics have demonstrated clinical- and patient-reported benefits, they are expensive and difficult to obtain for patients. The process is quite cumbersome and often requires facilitation by a subspecialist. The AERD Clinic acts as a referral centre for patients to be thoroughly assessed by the relevant specialists and provides the necessary treatment (aspirin desensitization therapy, surgery, and/or biologics) to manage their disease. NERD patients can be referred through Pathways or can fax the referral form [Figure 2]. We have adapted previously published protocols [Table 1][12] to work within the constraints of the BC health care system.

Since November 2021, 10 patients have been desensitized at the AERD/NERD clinic. One of those patients has very severe sinus disease and had multiple sinus surgeries. The patient’s “asthma was so bad [they were] waking up during the night to take [their] inhalers. The polyps kept growing, even after surgery. By 2021, [the polyps] got so bad, they were pressing against [their] eye, and [they] almost lost [their] vision.” “[They] had surgery again and aspirin desensitization therapy in March, and it’s changed everything.”[11]

When to refer

Any patient with the full triad of NERD symptoms or asthma and chronic rhinosinusitis with nasal polyposis should be assessed. NSAID hypersensitivity can be difficult to elicit in history, and many patients will require an ASA challenge.


NERD is a complex airway disease that requires subspecialized care from multiple health care providers to optimize outcomes. In BC, greater awareness of NERD is needed to provide early diagnosis and appropriate management. French researchers described NERD in 1922, but it was largely unnoticed until Samter and Beers published their landmark case series 46 years later.[7] We hope to bring NERD to the forefront in BC in a timelier manner.

Competing interests

None declared.

This article has been peer reviewed.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


1.    Li KL, Lee AY, Abuzeid WM. Aspirin exacerbated respiratory disease: Epidemiology, pathophysiology, and management. Med Sci 2019;7:45.

2.    Taniguchi M, Mitsui C, Hayashi H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. Allergol Int 2019;68:289-295.

3.    Pleskow WW, Stevenson DD, Mathison DA, et al. Aspirin-sensitive rhinosinusitis/asthma: Spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983;71:574-579.

4.    Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-485.

5.    Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-975.

6.    Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery: A recurrence analysis. Ann Otol, Rhinol Laryngol 2011;120:162-166.

7.    Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Aspirin exacerbated respiratory disease: Current topics and trends. Respir Med 2018;135:62-75.

8.    Chu DK, Lee DJ, Lee KM, et al., editors. Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: A systematic review and meta-analysis. Int Forum Allergy Rhinol 2019;9:1409-1419.

9.    Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol 2015;135:676-681.e1.

10.    Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019;394(10209):1638-1650.

11.    Last L. An Aspirin a day can keep the polyps at bay. The Daily Scan. 20 December 2022. Accessed 23 May 2023. https://thedailyscan.providencehealthcare.org/2022/12/an-aspirin-a-day-can-keep-the-polyps-at-bay.

12.    DeGregorio GA, Singer J, Cahill KN, Laidlaw T. A one-day, 90-minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2019;7:1174-1180.

13.    US Food and Drug Administration. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Last updated 13 March 2020. Accessed 23 May 2023. www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug.

14.    Noller M, Fischer JL, Gudis DA, Riley CA. The Draf III procedure: A review of indications and techniques. World J Otorhinolaryngol Head Neck Surg 2022;8:1-7.

15.    Oykhman P, Paramo FA, Bousquet J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol 2022;149:1286-1295.

16.    Yong M, Wu YQ, Howlett J, et al. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 2021; 11:1626-1636.

17.    San Nicoló M, Habermann N, Havel M. AERD associated nasal polyposis: Efficacy of postoperative antileukotriene therapy in comparison with aspirin desensitization. A retrospective study. Int Arch Allergy Immunol 2020;181:790-798.

Dr Cherukupalli is a resident doctor in the Division of Otolaryngology – Head and Neck Surgery, Department of Surgery, Faculty of Medicine, University of British Columbia. Dr Thamboo is a clinical associate professor in the Division of Otolaryngology – Head and Neck Surgery, Department of Surgery, Faculty of Medicine, UBC. Dr Ruiz is a clinical instructor in the Division of Allergy and Immunology, Faculty of Medicine, UBC.

A. Cherukupalli, MD, MHSc, A. Thamboo, MD, MHSc, FRCSC, J.C. Ruiz, MD, FRCPC. NSAID-exacerbated respiratory disease: Clinical review and referral pathway in British Columbia. BCMJ, Vol. 65, No. 7, September, 2023, Page(s) 248-252 - Clinical Articles.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply